Torsemide and Spironolactone tablet — Competitive Intelligence Brief

Torsemide and Spironolactone tablet (Torsemide and Spironolactone tablet) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Loop diuretic and potassium-sparing diuretic. Area: Cardiovascular.

phase 3 Loop diuretic and potassium-sparing diuretic Sodium-potassium-chloride cotransporter (NKCC2) and Aldosterone receptor Cardiovascular Small molecule

Target snapshot

Torsemide and Spironolactone tablet (Torsemide and Spironolactone tablet) — Sarfez Pharmaceuticals, Inc.. Torsemide is a loop diuretic that works by inhibiting the sodium-potassium-chloride cotransporter in the ascending limb of the loop of Henle, while spironolactone is a potassium-sparing diuretic that works by antagonizing the aldosterone receptor.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Torsemide and Spironolactone tablet TARGET	Torsemide and Spironolactone tablet	Sarfez Pharmaceuticals, Inc.	phase 3	Loop diuretic and potassium-sparing diuretic	Sodium-potassium-chloride cotransporter (NKCC2) and Aldosterone receptor
Torsemide Tablets and Spironolactone Tablets	Torsemide Tablets and Spironolactone Tablets	Sarfez Pharmaceuticals, Inc.	phase 3	Loop diuretic and potassium-sparing diuretic	Sodium-chloride cotransporter and Mineralocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Loop diuretic and potassium-sparing diuretic class)

1. Sarfez Pharmaceuticals, Inc. · 2 drugs in this class